Since Joining Edwards Lifesciences in 2015 Matt has been part of the Global Health Economics and Reimbursement (GHER) team working to remove economic barriers, develop value messages, reimbursement strategies, and improve patient access to surgical heart valve products. Most recently this includes obtaining a New Technology Add-on Payment (NTAP) designation from CMS for the EDWARDS INTUITY Elite valve system that went into effect October 1, 2017. Matt also monitors the shift from volume to value in our payment landscape including bundled payment models and other CMMI initiatives as well as the evolution of the Quality Payment Program and how this shift will impact our customers and patients.
Prior to joining Edwards Lifesciences Matt was employed at Hull Associates, a Boston based firm that specializes in developing market access and reimbursement strategies in global markets, and holds a PhD in Medical Physiology and Pharmacology from the University of Missouri.